Inozyme Pharmaceuticals aims to develop a therapy for an ultra-rare infant disorder—this is based on the work of Yale University pathologist Demetrios Braddock.

Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease

$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come